LYB001
LYB001| 백신 설명 | |
|---|---|
| 대상 | 사스-CoV-2 |
| 백신 종류 | 바이러스성 입자 |
| 임상 데이터 | |
| 루트 행정부. | 근육 내 |
| 의 시리즈의 일부 |
| COVID-19 대유행 |
|---|
|
| |
LYB001은 Yantai Patronus Biotec Co.,[1][2][3][4] Ltd.에 의해 개발된 COVID-19 백신 후보이다.
레퍼런스
- ^ "Safety, Reactogenicity, and Immunogenicity of a Recombinant SARS-CoV-2 Vaccine LYB001 in healthy adults: a randomized, double blinded, placebo-controlled phase I trial". chictr.org.cn. Chinese Clinical Trial Registry. Retrieved 15 October 2021.
- ^ "A Phase I Trial to Evaluate the Safety and Immunogenicity of SARS-CoV-2 Vaccine LYB001". ClinicalTrials.gov. 18 November 2021. NCT05125926. Retrieved 18 November 2021.
- ^ "Immunogenicity and safety of a SARS-CoV-2 Vaccine LYB001 against COVID-19 in healthy adults: a randomized, double blinded, placebo-controlled phase II trial and a single-armed, open-label expanded safety phase III trial". chictr.org.cn. Chinese Clinical Trial Registry. Retrieved 15 October 2021.
- ^ "Phase II and III Trial of a SARS-CoV-2 Vaccine LYB001". ClinicalTrials.gov. 30 November 2021. NCT05137444. Retrieved 30 November 2021.
| 스콜리아는 LYB001(Q110269779)에 대한 프로필을 가지고 있습니다. |